Skip to main content
Loading...
Menu social network
LinkedIn
Facebook
X
Youtube
Menu top
Assistance
User account menu
Log in
Main navigation
Home
Programme
Download the app
App
Download the app
App
Menu
Login
Close
Main navigation mobile
Home
Programme
Menu top
Assistance
Menu social network
LinkedIn
Facebook
X
Youtube
94 results
- D3.110 - Contribution of biotherapies in the reintroduction of NSAIDs in patients with moderate to severe asthma, hypersensitive to COX-1 inhibitor NSAIDs
- D3.111 - Lymphocyte profile and asthma control during the treatment with benralizumab in real life
- D3.113 - In silico system pharmacology modeling provides insights into a mechanism for greater potency of TSLP/TSLPR pathway inhibition with verekitug, a novel antibody antagonist of TSLPR, as compared to tezepelumab
- D3.114 - Does severe asthma exist in preschool children?
- D3.116 - Mepolizumab as game changer in a case of severe occupational asthma with rhinitis and contact dermatitis
- D3.117 - Targeting Mast Cells with Briquilimab, an Anti-Human c-Kit (CD117) Antibody, Mitigates COPD-Like Features in an Allergen and Cigarette Smoke-Exacerbated Asthma Model Using Humanized h/mCD117 Mice
- D3.119 - Selection of Biologics for Severe Pediatric Asthma with Allergic Eosinophilic Phenotype
- D3.123 - Dupilumab: Improved Asthma Control and Quality of Life in Pediatric Patients - A Real-World, Single-Center Study
- D3.13 - Real-life experience with tezepelumab in severe allergic asthma
D3.344 - Biological therapy for severe chronic spontaneous urticaria associated with autoimmune atrophic gastritis
D3.364 - Effect of Omalizumab on Inflammatory and Immune Biomarkers in Mast Cell-Mediated Angioedema
D3.97 - Postoperative Anti-IgE Therapy for Chronic Rhinosinusitis with Nasal Polyps and Asthma: Efficacy and Prognostic Factors
- D3.99 - Early Real-World Outcomes of Tezepelumab in Severe Asthma Patients Unresponsive to Prior Biologics
D3.138 - Asthma remission in EGPA patients: applicability and concordance of the main international guidelines
D3.23 - Descriptive and Comparative Analysis of Clinical and Endoscopic Characteristics and Treatment Response in Adult Patients with Eosinophilic Esophagitis (EoE): a preliminary experience of an Italian centre
D3.26 - Anaphylaxis associated with biosimilar Tocilizumab: in vitro and in vivo diagnosis
D3.274 - Succesful Omalizumab Desensitization in Two Children with Severe Allergic Asthma and Cronic Spontaneous Urticaria
D3.28 - Comparative Efficacy and Safety of Omalizumab Intended copy Biosimilar vs. Biologic in Chronic Spontaneous Urticaria
D3.283 - Taming the Unpredictable: Omalizumab’s Role in Idiopathic anaphylaxis and chronic spontaneous urticaria
D3.29 - Detailed Clinical Characterization of a Large Cohort of Chronic Spontaneous Urticaria Patients
Pagination
First page
First
Previous page
Previous
Page
1
Page
2
Current page
3
Page
4
Page
5
Next page
Next
Last page
Last
Download the app
The congress at your fingertips
Available on
Download